

Opposing effects of rapamycin and cyclosporin A on activation-induced Ca^{2+} release

Wassim Y. Almawi^{a,b,*}, Joumana W. Assi^b, Dagmara M. Chudzik^b, Andrew I. Lazarovits^b

^a Molecular Biology Section, Department of Laboratory Medicine, St. Georges Hospital, Beirut, Lebanon

^b Department of Medicine, University of Western Ontario, London, Ontario, Canada

Received 12 April 1999; received in revised form 23 July 1999; accepted 30 July 1999

Abstract

Insofar as Ca^{2+} plays a major role in T cell activation, we investigated the effect of the immunosuppressants cyclosporin A and rapamycin on T cell proliferation and on the activation-induced increase in $[\text{Ca}^{2+}]_i$. Both cyclosporin A and rapamycin inhibited mitogen (concanavalin A and phytohemagglutinin) and ionomycin + phorbol myristate acetate (PMA)-driven T cell proliferation (Ca^{2+} -dependent). However, only rapamycin suppressed T cell proliferation stimulated by anti-CD28 antibody (Ab) + PMA, and recombinant interleukin-6-stimulated proliferation of the interleukin-6 dependent B9 cells (Ca^{2+} -independent). These differences were associated with a different effect of both drugs on Ca^{2+} release, as cyclosporin A attenuated while rapamycin augmented the mitogen-induced elevation in $[\text{Ca}^{2+}]_i$. Collectively, this supports the notion that Ca^{2+} is required in early stages of T cell activation, and that cyclosporin A blocked only Ca^{2+} -dependent while rapamycin blocked both Ca^{2+} -dependent and -independent events of T cell activation. © 1999 Elsevier Science B.V. All rights reserved.

Keywords: Cyclosporin A; Rapamycin; Ca^{2+} ; T cells; EGTA (ethylene glycol-bis (β -aminoethyl ether) N,N,N',N' -tetraacetic acid)

1. Introduction

T cell activation through the T cell receptor/CD3 complex in conjunction with appropriate costimulation involves rapid phosphorylation of several intra-cellular molecules by src-like protein tyrosine kinases, and results in the activation of protein kinase C, elevation of intra-cellular Ca^{2+} ($[\text{Ca}^{2+}]_i$), and induction of the interleukin-2 autocrine pathway. An orderly expression of cytokine genes and their high-affinity receptors ensues, followed by induction of cellular proliferation (Almawi et al., 1998). This Ca^{2+} -dependent phase of T cell activation is followed by a Ca^{2+} -independent phase, as exemplified by the interaction of T cell-bound CD28/CTLA-4 with accessory cell-bound B7.1/B7.2 (June et al., 1987), or by the interaction of cytokines with their high-affinity receptors.

Cyclosporin A and rapamycin are potent immunosuppressive drugs that exert their effects by inhibiting distinct events of the T cell activation cascade (Halloran, 1996), but synergize in inhibiting T cell immunity (Wasowska et al., 1997). Both drugs act by binding to their cytosolic receptors. Cyclosporin A binds cyclophilin (Almawi et al., 1993), thereby antagonizing calcineurin activity and hence interrupting signal transduction events that link T cell receptor engagement to induction of cytokine expression (Emmel et al., 1989). Rapamycin, by binding to the FK506-binding protein of 12 Mr kDa (FKBP12; Sabers et al., 1995), antagonizes biochemical events associated with cytokine-stimulated signaling events or those associated with cross-linking of the CD28 homodimer (Almawi et al., 1993).

In view of the central role of Ca^{2+} in driving optimal T cell activation, and the different requirement for Ca^{2+} at distinct stages of T cell activation, we investigated the effects of cyclosporin A and rapamycin on Ca^{2+} -dependent and -independent proliferative responses and on the activation driven increase in $[\text{Ca}^{2+}]_i$. Results obtained clearly support the notion that cyclosporin A blocks the Ca^{2+} -dependent response, whereas rapamycin blocks both Ca^{2+} -dependent and -independent events of T cell activation.

* Corresponding author. Section of Molecular Biology, Department of Laboratory Medicine, St. Georges-Orthodox Hospital, P.O. Box 166378-6417, Beirut, Lebanon. Tel.: +961-3-812861; fax: +961-1-582560; e-mail: wyalmawi@aub.edu.lb

2. Materials and methods

2.1. Preparation of peripheral blood mononuclear cells

Peripheral blood mononuclear cells were prepared from the venous blood of healthy volunteers by hypaque-ficoll (sg 1.076) sedimentation (Pharmacia Fine Chemicals, Dorval, Canada). The interphase containing peripheral blood mononuclear cells was suspended in RPMI-1640 culture medium supplemented with 10% human AB serum (Whittaker, Bethesda, MD), 2 mM L-glutamine (Gibco BRL, Mississauga, Canada), and penicillin–streptomycin (Gibco BRL) at 100 IU/ml and 100 µg/ml, respectively. This medium is referred to thereafter as “complete medium”. Cell viability was determined by the Trypan blue exclusion method.

2.2. Reagents and drugs

Phorbol myristate acetate (PMA), concanavalin A, ethylene glycol-bis (β-aminoethyl ether) *N,N,N',N'*-tetraacetic acid (EGTA), and ionomycin were obtained from Sigma (St. Louis, MO), and phytohemagglutinin was purchased from Difco Laboratories (Detroit, MI). Cyclosporin A (Sandoz, Basel, Switzerland) and rapamycin (Wyeth-

Ayerst; Princeton, NJ) were prepared as 10 mM stocks in 70% ethanol; further dilutions were made with RPMI-1640. The anti-CD28 antibody (Ab), 9.3, was generously provided by Bristol-Myers-Squibb (Philadelphia, PA), and the interleukin-6 sensitive cell line, B9, was kindly supplied by Dr. L. Aarden (Amsterdam, the Netherlands). Recombinant IL-6 was kindly donated by Dr. Steven Gillis (Immunex, Seattle, WA).

2.3. Proliferation assay

Peripheral blood mononuclear cells (10^6 cells/ml) were cultured in 96-well flat-bottom microtiter plates, treated with drugs or controls, stimulated and incubated for 72 h at 37°C. B9 cells (2×10^5 cells/ml) were similarly cultured and treated, stimulated with recombinant interleukin-6 (200 U/ml), and incubated for 48 h at 37°C. [^3H]Thymidine (Dupont-NEN, Mississauga, Canada) was added to the plates (1 µCi/well) 4 h prior to termination of culture; cellular proliferation (in counts per minute; CPM) was quantitated by liquid scintillation.

2.4. Measurement of $[\text{Ca}^{2+}]_i$ levels

$[\text{Ca}^{2+}]_i$ levels were determined by flow cytometry on FACStar Plus (Becton-Dickinson, Toronto, Canada), using




Fig. 1. Calcium mobilization in response to phytohemagglutinin stimulation. Medium: ethanol (A), rapamycin (B), and cyclosporin A (C) pretreated and Indo-1AM-loaded peripheral blood mononuclear cells were stimulated with phytohemagglutinin (25 µg/ml); changes in $[\text{Ca}^{2+}]_i$ were determined by flow cytometry.

the acetoxymethylester of indo-1 (Indo-1AM) (Sigma) as indicator dye. Briefly, peripheral blood mononuclear cells (10^6 cells/ml) were treated with drugs or vehicle for the indicated time periods and loaded with Indo-1AM ($10 \mu\text{g/ml}$) in the dark for 45 min at 37°C . The cells were then washed, resuspended at 10^7 cells/ml, and stimulated with phytohemagglutinin ($25 \mu\text{g/ml}$). $[\text{Ca}^{2+}]_i$ levels were measured by recording the shift in fluorescence (excitation wavelength, 339 nm; emission wavelength, 492 nm) before and after phytohemagglutinin addition over a 10-min period. The change in Ca^{2+} concentrations was calculated as described by Muthukkumar et al. (1993).

3. Results

3.1. Effect of cyclosporin A and rapamycin on Ca^{2+} release

Peripheral blood mononuclear cells were pretreated for 4–6 h with ethanol (solvent), cyclosporin A or rapamycin at the indicated concentrations, preloaded with Indo-1AM in the dark, and stimulated with the mitogen phytohemagglutinin. Changes in $[\text{Ca}^{2+}]_i$ were recorded 2.2 min before (baseline) and over a 7.8-min period after mitogen addition. Mitogen-induced stimulation resulted in a rapid rise in $[\text{Ca}^{2+}]_i$ which was maximal 4.8 min after mitogen addition (Fig. 1). Whereas, cyclosporin A attenuated the




Fig. 2. Kinetics of cyclosporin A and rapamycin action. Percent change in $[\text{Ca}^{2+}]_i$ in peripheral blood mononuclear cells treated with cyclosporin A and rapamycin at $1 \mu\text{M}$ each at the indicated time before or after phytohemagglutinin ($25 \mu\text{g/ml}$) addition relative to the $[\text{Ca}^{2+}]_i$ change in ethanol-pretreated cultures. Results shown represent the mean of four experiments. $[\text{Ca}^{2+}]_i$ levels (mean \pm S.E.M.), resting (non-stimulated) cells, 124 ± 22 nM, phytohemagglutinin-activated cells, 295 ± 32 nM.




Fig. 3. Effect of cyclosporin A and rapamycin on $[\text{Ca}^{2+}]_i$ in the presence or absence of EGTA. Percent change in $[\text{Ca}^{2+}]_i$ in PBML pretreated for 4 h with cyclosporin A (CsA) and rapamycin (Rapa) (at $1 \mu\text{M}$ each) or a corresponding volume of ethanol (Control), loaded with Indo-1AM, and stimulated with phytohemagglutinin in the presence (+EGTA) or absence (–EGTA) of the calcium chelator, EGTA (5 mM). Results shown are the mean of six individually performed experiments.

mitogen-stimulated rise in $[\text{Ca}^{2+}]_i$, rapamycin augmented it (Fig. 1), as compared to $[\text{Ca}^{2+}]_i$ levels in medium- or ethanol-pretreated and stimulated cultures.

The inhibitory and stimulatory effects of cyclosporin A and rapamycin, respectively, on mitogen-stimulated Ca^{2+} release were seen at concentrations as low as 1 nM for each drug, reaching a maximum at $1 \mu\text{M}$ or higher. It is noteworthy that neither drug was capable of altering basal (non-stimulated) Ca^{2+} concentrations, and that cyclosporin A, while clearly attenuating the activation-induced rise in $[\text{Ca}^{2+}]_i$, did not abolish it completely (Fig. 1).

3.2. Kinetics of cyclosporin A and rapamycin action

The time dependency of cyclosporin A and rapamycin action in attenuating and augmenting $[\text{Ca}^{2+}]_i$, respectively, was next examined. Cyclosporin A and rapamycin, each at a final concentration of $1 \mu\text{M}$, were added before, at, or after mitogen addition to Indo-1AM-loaded cultures; percent changes in $[\text{Ca}^{2+}]_i$ were recorded over a 10-min period after their addition, and were made in reference to control cultures treated with a corresponding volume of ethanol. Cyclosporin A attenuated the activation-stimulated rise in $[\text{Ca}^{2+}]_i$ only if added before or at the same time as phytohemagglutinin; its addition after mitogen stimulation was ineffective (Fig. 2). In contrast, rapamycin augmented the mitogen-stimulated rise in $[\text{Ca}^{2+}]_i$ even if added after activation (Fig. 2).




Fig. 4. Suppression of Ca^{2+} -dependent proliferative responses by cyclosporin A and rapamycin. Percent suppression of T cell proliferation stimulated by concanavalin A (5 $\mu\text{g/ml}$; left), or PMA (5 ng/ml) + ionomycin (0.1 μM) (right). Results shown are the means of eight individually performed experiments. Proliferation values (in CPM): background, 128 ± 18 ; Concanavalin A, 67790 ± 12593 ; PMA + ionomycin, 82486 ± 12043 . Percent suppression was calculated as per: $\{1 - [(\text{test-background})/(\text{control-background})]\} \times 100\%$.

3.3. Effect of Ca^{2+} chelation on cyclosporin A and rapamycin effects on $[\text{Ca}^{2+}]_i$

We next determined whether the attenuation and augmentation of the mitogen-stimulated rise in $[\text{Ca}^{2+}]_i$ mediated by cyclosporin A and rapamycin, respectively, was dependent on extracellular Ca^{2+} influx. Indo-1AM-loaded cultures treated with cyclosporin A, rapamycin, or a corresponding volume of ethanol (Control) were treated with the Ca^{2+} chelator, EGTA (5 mM; +EGTA) or control (–EGTA), and stimulated with phytohemagglutinin. Results from Fig. 3 show that EGTA completely abolished the stimulated rise in $[\text{Ca}^{2+}]_i$, in cyclosporin A-treated

cultures. It was of interest to find that EGTA only partially suppressed the mitogen-induced rise in $[\text{Ca}^{2+}]_i$ in rapamycin-treated cultures (Fig. 3), an indication that the rapamycin-augmented rise in $[\text{Ca}^{2+}]_i$ follows both Ca^{2+} -dependent and -independent pathways.

3.4. Effect of cyclosporin A and rapamycin on proliferative responses

Insofar as T cell activation follows Ca^{2+} -dependent and -independent pathways, and as cyclosporin A and rapamycin differentially affected the activation-induced rise in $[\text{Ca}^{2+}]_i$, we next assessed the effect of cyclosporin A




Fig. 5. Suppression of Ca^{2+} -independent proliferative responses by cyclosporin A and rapamycin. Percent suppression of T cell proliferation stimulated by cross-linking anti-CD28 Ab (1:200) + PMA (5 ng/ml) (left), and recombinant interleukin-6-driven proliferation of B9 cells (right). Shown is the mean of eight (PBML) or four (B9 cells) individually performed experiments. Proliferation values (in CPM): peripheral blood mononuclear cells: background, 1291 ± 404 ; anti-CD28 Ab + PMA, 73011 ± 5948 ; B9 cells: background, 217 ± 51 ; rIL-6, 20125 ± 1585 . Percent suppression was calculated as per Fig. 4.

and rapamycin on Ca^{2+} -dependent and independent T cell proliferation. The former was elicited by the mitogens phytohemagglutinin and concanavalin A, and the “CD3-bypass” stimulation regimen, PMA + ionomycin. The latter was achieved by cross-linking of T cell bound CD28 with the anti-CD28 Ab, 9.3 in conjunction with PMA, and by stimulation of the interleukin-6 dependent cell line, B9, with recombinant interleukin-6.

Whereas, both cyclosporin A and rapamycin, in a concentration-dependent manner, inhibited both concanavalin A and PMA + ionomycin (Ca^{2+} -dependent) proliferative responses (Fig. 4), only rapamycin blocked anti-CD28 Ab + PMA T cell and recombinant interleukin-6-driven B9 cell (Ca^{2+} -independent) proliferation (Fig. 5). The inhibitory effect of cyclosporin A on recombinant interleukin-6 stimulated proliferation of B9 cells seen at 10 μM or higher concentrations reflects a non-specific cytotoxic effect, as this was associated with a significant reduction in cell viability (data not shown).

4. Discussion

The results reported here demonstrate that cyclosporin A blocked Ca^{2+} dependent whereas rapamycin blocked both Ca^{2+} -dependent and -independent proliferative responses, and that cyclosporin A attenuated while rapamycin augmented the activation-induced rise in $[\text{Ca}^{2+}]_i$. Although the inhibitory effect of cyclosporin A on Ca^{2+} -dependent T cell effector function (i.e., proliferation and interleukin-2 secretion) is well established, its effect on the T cell activation-induced rise in $[\text{Ca}^{2+}]_i$ is controversial, as some reports described an inhibitory (Draberova, 1990), stimulatory (Damjanovich et al., 1987), or no effect (Harris et al., 1987; Muthukumar et al., 1993) of cyclosporin A on $[\text{Ca}^{2+}]_i$. In these studies, the effect of cyclosporin A was assessed in cloned cytotoxic T lymphocytes (Harris et al., 1987), anti-immunoglobulin M (IgM)-stimulated immature B cells (Muthukumar et al., 1993), mast cells (Draberova, 1990), or under highly artificial conditions (Damjanovich et al., 1987). While not negating earlier findings, it appears that the effect of cyclosporin A on $[\text{Ca}^{2+}]_i$ depends on the cell type investigated, and the experimental conditions utilized.

While the effect of cyclosporin A on Ca^{2+} -dependent proliferation and the rise in $[\text{Ca}^{2+}]_i$ were not surprising in light of its effect on Ca^{2+} -dependent events of T cell activation (activation of calcineurin, induction of cytokine gene expression) (Emmel et al., 1989), it was of interest — and the first demonstration in human lymphocytes — that rapamycin augmented the $[\text{Ca}^{2+}]_i$ rise elicited in mitogen- (Fig. 1) and anti-CD3 Ab-stimulated (data not shown) human peripheral blood mononuclear cells. While it clearly augmented the activation-induced rise in $[\text{Ca}^{2+}]_i$, rapamycin apparently did not affect basal (non-stimulated) Ca^{2+} levels, which suggested that other “activation-asso-

ciated” signals must cooperate with rapamycin in stimulating an increase in $[\text{Ca}^{2+}]_i$. Furthermore, cyclosporin A acted proximally since its addition after mitogen stimulation abolished its attenuation of the activation-induced rise in $[\text{Ca}^{2+}]_i$. In contrast, rapamycin appeared to act more distally since its introduction (even 30 min post-activation) resulted in a significant rise in $[\text{Ca}^{2+}]_i$.

This was further shown in the EGTA studies, where chelation of extracellular Ca^{2+} partially abolished the rapamycin-mediated augmentation in $[\text{Ca}^{2+}]_i$, which was unexpected since EGTA was previously shown, and confirmed here, to abolish the mitogen-stimulated increase in $[\text{Ca}^{2+}]_i$ (Watman et al., 1988; Komada et al., 1996). However, mitogen-stimulated proliferation requires other signals imparted by accessory cells in addition to extracellular Ca^{2+} . In reducing the availability of $[\text{Ca}^{2+}]_i$, EGTA may have affected early proximal events of T cell activation, without rendering the cells anergic (Watman et al., 1988). Accordingly, activation of intracellular Ca^{2+} pools directly by rapamycin (in conjunction with other signals) stimulated an increase in $[\text{Ca}^{2+}]_i$ that was independent of extracellular Ca^{2+} (i.e., “ Ca^{2+} -evoked Ca^{2+} release”). This was supported by studies which demonstrated that, by binding FKBP-12, rapamycin destabilizes its tight association with $[\text{Ca}^{2+}]_i$ -release channels (ryanodine receptors or IP3 receptors) in striated (Ahern et al., 1997) and non-striated (Graves et al., 1997; Marks, 1997) cells, resulting in significant accumulation of $[\text{Ca}^{2+}]_i$ (Ahern et al., 1997; Marks, 1997).

Mechanistically, cyclosporin A blocks T cell activation specifically by antagonizing calcineurin activity (Takahashi et al., 1989), thus preventing the correct import of nuclear factors required for optimal transcription of interleukin-2 and other cytokine genes (Emmel et al., 1989). Rapamycin acts later in the T cell activation pathway, and its target of action appears to be ribosomal p70S6 kinase, a key Ca^{2+} -regulated enzyme involved in signaling via cytokine and growth factor receptors (Calvo et al., 1992; Graves et al., 1997). Thus, by differentially affecting the activation-induced rise in $[\text{Ca}^{2+}]_i$, cyclosporin A and rapamycin selectively affected distinct events of T cell activation whereby cyclosporin A blocked only Ca^{2+} -dependent, while rapamycin blocked both Ca^{2+} -dependent and Ca^{2+} -independent T cell proliferation. The significance of the rapamycin-mediated potentiation of the T cell activation-induced rise in $[\text{Ca}^{2+}]_i$ on its anti-proliferative effect remains to be determined.

Acknowledgements

The authors wish to thank Martin White for his assistance in the FACS analysis, and Dr. Anthony M. Jevnikar and Dr. Calvin R. Stiller for their helpful suggestions. The work was supported by grants from the Kidney Foundation of Canada and the Hospital for Sick Children Foundation.

References

- Ahern, G.P., Junankar, P.R., Dulhunty, A.F., 1997. Ryanodine receptors from rabbit skeletal muscles are reversibly activated by rapamycin. *Neurosci. Lett.* 225, 81–84.
- Almawi, W.Y., Stevens, A.C., Lipman, M.L., 1993. Immunosuppressive drugs acting through inhibition of cytokine expression. In: Oppenheim, J.J., Russo, A.J.H., Kluger, M. (Eds.), *Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy*. Oxford Univ. Press, Oxford, U.K., pp. 269–273.
- Almawi, W.Y., Hess, D.A., Rieder, M.J., 1998. Multiplicity of glucocorticoid action in inhibiting allograft rejection. *Cell Transplant.* 7, 511–523.
- Calvo, V., Crews, C.M., Vik, T.A., Bierer, B.E., 1992. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. *Proc. Natl. Acad. Sci. U.S.A.* 89, 7571–7575.
- Damjanovich, S., Aszalos, A., Mulhern, S.A., Szollosi, J., Balazs, M., Tron, L., Fulwyler, M.J., 1987. Cyclosporin depolarizes human lymphocytes: earliest observed effect on cell metabolism. *Eur. J. Immunol.* 17, 763–768.
- Draberova, E., 1990. Cyclosporin A inhibits rat mast cell activation. *Eur. J. Immunol.* 20, 1469–1473.
- Emmel, E.A., Verweij, C.L., Durand, D.B., Higgins, K.M., Lacy, E., Crabtree, G.R., 1989. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. *Science* 246, 1617–1620.
- Graves, L.M., He, Y., Lambert, J., Hunter, D., Li, X., Earp, H.S., 1997. An intracellular calcium signal activates p70 but not p90 ribosomal S6 kinase in liver epithelial cells. *J. Biol. Chem.* 272, 1920–1928.
- Halloran, P.F., 1996. Molecular mechanisms of new immunosuppressants. *Clin. Transplant.* 10, 118–123.
- Harris, D.T., Kozumbo, W.J., Cerrutti, P.A., Cerottini, J.-C., 1987. Mechanism of cyclosporin A-induced immunosuppression. Cyclosporin A inhibits receptor-mediated and non-receptor-mediated lymphokine production as well as interleukin-2-induced proliferation in cloned T lymphocytes. *Cell. Immunol.* 109, 104–114.
- June, C.H., Ledbetter, J.A., Gillespie, M.M., Lindsten, T., Thompson, C.B., 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporin-resistant interleukin 2 gene expression. *Mol. Cell. Biol.* 7, 4472–4478.
- Komada, H., Nakabayashi, H., Hara, M., Izutsu, K., 1996. Early calcium signaling and calcium requirements for the IL-2 receptor expression and IL-2 production in stimulated lymphocytes. *Cell. Immunol.* 173, 215–220.
- Marks, A.R., 1997. Intracellular calcium-release channels: regulators of cell life and death. *Am. J. Physiol.* 272, H597–H605.
- Muthukkumar, S., Udhayakumar, V., Bondada, S., 1993. Elevation of cytosolic calcium is sufficient to induce growth inhibition in a B cell lymphoma. *Eur. J. Immunol.* 23, 2419–2426.
- Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont, F.J., Wiederrecht, G., Abraham, R.T., 1995. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. *J. Biol. Chem.* 270, 815–822.
- Takahashi, N., Hayano, T., Suzuki, M., 1989. Peptidyl-prolyl *cis*–*trans* isomerase is the cyclosporin A-binding protein cyclophilin. *Nature* 337, 473–475.
- Wasowska, B., Hancock, W.W., Onodera, K., Korom, S., Stadlbauer, T.H.W., Zheng, X.X., Strom, T.B., Kupiec-Weglinski, K., 1997. Rapamycin and cyclosporin A treatment: a novel regimen to prevent chronic allograft rejection in sensitized hosts. *Transplant. Proc.* 29, 333.
- Watman, N.P., Crespo, L., Davis, B., Poiesz, B.J., Zamkoff, K.W., 1988. Differential effect on fresh and cultured T cells of PHYTOHEMAGGLUTININ-induced changes in free cytoplasmic calcium: relation to IL-2 receptor expression, IL-2 production, and proliferation. *Cell. Immunol.* 111, 158–166.